Published in Cancer J on June 25, 2016
Immunotherapy for the treatment of colorectal tumors: focus on approved and in-clinical-trial monoclonal antibodies. Drug Des Devel Ther (2017) 0.75
Oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment for colon cancer. N Engl J Med (2004) 18.93
Levamisole and fluorouracil for adjuvant therapy of resected colon carcinoma. N Engl J Med (1990) 11.57
Improved overall survival with oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment in stage II or III colon cancer in the MOSAIC trial. J Clin Oncol (2009) 9.24
CDX2 as a Prognostic Biomarker in Stage II and Stage III Colon Cancer. N Engl J Med (2016) 8.53
Oxaliplatin combined with weekly bolus fluorouracil and leucovorin as surgical adjuvant chemotherapy for stage II and III colon cancer: results from NSABP C-07. J Clin Oncol (2007) 7.73
A pooled analysis of adjuvant chemotherapy for resected colon cancer in elderly patients. N Engl J Med (2001) 7.59
Pooled analysis of fluorouracil-based adjuvant therapy for stage II and III colon cancer: who benefits and by how much? J Clin Oncol (2004) 7.36
Defective mismatch repair as a predictive marker for lack of efficacy of fluorouracil-based adjuvant therapy in colon cancer. J Clin Oncol (2010) 6.87
Capecitabine as adjuvant treatment for stage III colon cancer. N Engl J Med (2005) 6.22
Colon cancer survival is associated with increasing number of lymph nodes analyzed: a secondary survey of intergroup trial INT-0089. J Clin Oncol (2003) 5.71
Prognostic factors in colorectal cancer. College of American Pathologists Consensus Statement 1999. Arch Pathol Lab Med (2000) 5.68
Phase III trial assessing bevacizumab in stages II and III carcinoma of the colon: results of NSABP protocol C-08. J Clin Oncol (2010) 4.81
Irinotecan fluorouracil plus leucovorin is not superior to fluorouracil plus leucovorin alone as adjuvant treatment for stage III colon cancer: results of CALGB 89803. J Clin Oncol (2007) 4.32
Capecitabine plus oxaliplatin compared with fluorouracil and folinic acid as adjuvant therapy for stage III colon cancer. J Clin Oncol (2011) 3.99
Randomized phase III trial comparing biweekly infusional fluorouracil/leucovorin alone or with irinotecan in the adjuvant treatment of stage III colon cancer: PETACC-3. J Clin Oncol (2009) 3.69
Bevacizumab plus oxaliplatin-based chemotherapy as adjuvant treatment for colon cancer (AVANT): a phase 3 randomised controlled trial. Lancet Oncol (2012) 3.02
Adjuvant chemotherapy use and adverse events among older patients with stage III colon cancer. JAMA (2010) 2.93
Oxaliplatin as adjuvant therapy for colon cancer: updated results of NSABP C-07 trial, including survival and subset analyses. J Clin Oncol (2011) 2.88
Intergroup study of fluorouracil plus levamisole as adjuvant therapy for stage II/Dukes' B2 colon cancer. J Clin Oncol (1995) 2.02
A phase III randomised trial of LV5FU2 + irinotecan versus LV5FU2 alone in adjuvant high-risk colon cancer (FNCLCC Accord02/FFCD9802). Ann Oncol (2009) 1.92
FOLFOX and FLOX regimens for the adjuvant treatment of resected stage II and III colon cancer. Cancer Invest (2008) 1.56
Capecitabine Plus Oxaliplatin Compared With Fluorouracil/Folinic Acid As Adjuvant Therapy for Stage III Colon Cancer: Final Results of the NO16968 Randomized Controlled Phase III Trial. J Clin Oncol (2015) 1.03
Role of physical activity and diet after colorectal cancer diagnosis. J Clin Oncol (2015) 0.90
Hepatocellular carcinoma: consensus recommendations of the National Cancer Institute Clinical Trials Planning Meeting. J Clin Oncol (2010) 2.51
The impact of pre-operative loco-regional therapy on outcome after liver transplantation for hepatocellular carcinoma. Am J Transplant (2005) 1.90
Panitumumab monotherapy in patients with previously treated metastatic colorectal cancer. Cancer (2007) 1.52
Hepatocellular carcinoma: Ablate and wait versus rapid transplantation. Liver Transpl (2010) 1.26
Phase II study of the anti-cytotoxic T-lymphocyte-associated antigen 4 monoclonal antibody, tremelimumab, in patients with refractory metastatic colorectal cancer. J Clin Oncol (2010) 1.24
Dietary glycemic load and cancer recurrence and survival in patients with stage III colon cancer: findings from CALGB 89803. J Natl Cancer Inst (2012) 1.20
Vaccination of metastatic colorectal cancer patients with matured dendritic cells loaded with multiple major histocompatibility complex class I peptides. J Immunother (2007) 1.05
End points in advanced colon cancer clinical trials: a review and proposal. J Clin Oncol (2007) 0.95
Potent antitumor activity of cabozantinib, a c-MET and VEGFR2 inhibitor, in a colorectal cancer patient-derived tumor explant model. Int J Cancer (2014) 0.83
Phase II trial of T138067, a novel microtubule inhibitor, in patients with metastatic, refractory colorectal carcinoma. Clin Colorectal Cancer (2008) 0.79
Hepatocellular carcinoma: epidemic and treatment. Curr Oncol Rep (2004) 0.78
Treatment-related Hypertension as a Pharmacodynamic Biomarker for the Efficacy of Bevacizumab in Advanced Pancreas Cancer: A Pooled Analysis of 4 Prospective Trials of Gemcitabine-based Therapy With Bevacizumab. Am J Clin Oncol (2016) 0.78
Defining the role of hepatic arterial infusion chemotherapy in metastatic colorectal cancer. Oncology (Williston Park) (2004) 0.77
Impact of physical activity after cancer diagnosis on survival in patients with recurrent colon cancer: Findings from CALGB 89803/Alliance. Clin Colorectal Cancer (2013) 0.76
Complicated Case Presentation: Management of Pancreatic Neuroendocrine Tumors in Multiple Endocrine Neoplasia Type 1. Pancreas (2017) 0.75
Regional therapy of liver metastases. Curr Treat Options Oncol (2004) 0.75